UNIVASC
LOE ApproachingNDAORALTABLET
Approved
Apr 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
UNIVASC by UCB Pharma is mechanism of action moexipril hydrochloride is a prodrug for moexiprilat, which inhibits ace in humans and animals. First approved in 1995.
Drug data last refreshed 1h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UNIVASC (moexipril hydrochloride) is an oral ACE inhibitor approved in 1995 for hypertension management. It is a prodrug that converts to moexiprilat, which inhibits angiotensin-converting enzyme (ACE) to reduce vasoconstriction and lower blood pressure. The drug works by blocking the renin-angiotensin-aldosterone system, with demonstrated efficacy primarily in non-black populations.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (score: 30/100), indicating a consolidating team focused on generic transition planning and lifecycle extension strategies.
Mechanism of Action
Mechanism of Action Moexipril hydrochloride is a prodrug for moexiprilat, which inhibits ACE in humans and animals. The mechanism through which moexiprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes the conversion of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on UNIVASC at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.